Anzeige
Mehr »
Donnerstag, 11.09.2025 - Börsentäglich über 12.000 News
Diese Aktie sichert sich Exklusiv-Partnerschaft mit Babcock für Ukraine-Defence - Neubewertung voraus?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0ESMG | ISIN: FR0010259150 | Ticker-Symbol: I7G
Tradegate
11.09.25 | 09:18
119,60 Euro
+1,53 % +1,80
1-Jahres-Chart
IPSEN SA Chart 1 Jahr
5-Tage-Chart
IPSEN SA 5-Tage-Chart
RealtimeGeldBriefZeit
119,50119,8009:38
119,50119,8009:38

Aktuelle News zur IPSEN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiHealth Canada approves Medison and Ipsen's Bylvay to treat ALGS1
DiIpsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 36 - 20252
02.09.Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 35 - 20252
29.08.Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 34 - 20252
29.08.Zydus' phase 3 liver disease win tees up filing to challenge Gilead and Ipsen15
29.08.Zydus' phase 3 liver disease win tees up filing to challenge Gilead and Ipsen2
27.08.Ipsen Pharma: Ipsen - July 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital3
19.08.Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 33 - 20251
IPSEN Aktie jetzt für 0€ handeln
14.08.Ipsen receives EC approval for Cabometyx in advanced neuroendocrine tumours2
12.08.Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 20253
05.08.Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 20251
31.07.Ipsen S.A. reports 1H results, FY25 guidance4
31.07.Ipsen Pharma: Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025)2
31.07.Ipsen H1 Profit Rises On Sales Growth; Raises Annual Sales Outlook493PARIS (dpa-AFX) - Ipsen SA (IPSEY) Thursday reported net profit of 334 million euros or 4 euros per share for the first half, up from 232 million euros or 2.78 euros per share in the comparable...
► Artikel lesen
31.07.Ipsen Pharma: Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance565H1 total sales growth of 11.4% at CER1, or 9.7% as reported, driven by the three therapeutic areas: 95.7% in Rare Disease, 9.7% in Neuroscience, and 6.4% in OncologyH1 core operating income of €656m...
► Artikel lesen
29.07.Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 20251
24.07.Exelixis, Inc.: Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors729- Approval is based on the phase 3 CABINET pivotal trial, in which CABOMETYX demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo...
► Artikel lesen
24.07.Ipsen granted EU nod for Exelixis-partnered cancer drug for neuroendocrine tumors3
24.07.Ipsen Pharma: Cabometyx approved in the EU for previously treated advanced neuroendocrine tumors544Cabometyx® is the first and only systemic therapy to be approved in the European Union for previously treated unresectable or metastatic neuroendocrine tumors, regardless of tumor site, grade or previous...
► Artikel lesen
23.07.Ipsen Updates Executive Committee1
Weiter >>
74 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1